175 related articles for article (PubMed ID: 17603048)
41. A review of the metabolic effects of sibutramine.
Filippatos TD; Kiortsis DN; Liberopoulos EN; Mikhailidis DP; Elisaf MS
Curr Med Res Opin; 2005 Mar; 21(3):457-68. PubMed ID: 15811215
[TBL] [Abstract][Full Text] [Related]
42. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
43. The use of sibutramine in the management of obesity and related disorders: an update.
Tziomalos K; Krassas GE; Tzotzas T
Vasc Health Risk Manag; 2009; 5(1):441-52. PubMed ID: 19475780
[TBL] [Abstract][Full Text] [Related]
44. [Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents].
Corrêa LL; Platt MW; Carraro L; Moreira RO; Faria Júnior R; Godoy-Matos AF; Meirelles RM; Póvoa LC; Appolinário JC; Coutinho WF
Arq Bras Endocrinol Metabol; 2005 Apr; 49(2):286-90. PubMed ID: 16184258
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study.
Wilfley DE; Crow SJ; Hudson JI; Mitchell JE; Berkowitz RI; Blakesley V; Walsh BT;
Am J Psychiatry; 2008 Jan; 165(1):51-8. PubMed ID: 18056225
[TBL] [Abstract][Full Text] [Related]
46. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
Andersson C; Weeke P; Fosbøl EL; Brendorp B; Køber L; Coutinho W; Sharma AM; Van Gaal L; Finer N; James WP; Caterson ID; Rode RA; Torp-Pedersen C; ;
Metabolism; 2009 Aug; 58(8):1109-15. PubMed ID: 19454355
[TBL] [Abstract][Full Text] [Related]
47. Orlistat and sibutramine beyond weight loss.
Mannucci E; Dicembrini I; Rotella F; Rotella CM
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
[TBL] [Abstract][Full Text] [Related]
48. The effect of sibutramine on energy expenditure and body composition in obese adolescents.
Van Mil EG; Westerterp KR; Kester AD; Delemarre-van de Waal HA; Gerver WJ; Saris WH
J Clin Endocrinol Metab; 2007 Apr; 92(4):1409-14. PubMed ID: 17264187
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
Int J Obes Relat Metab Disord; 1998 Jan; 22(1):32-8. PubMed ID: 9481597
[TBL] [Abstract][Full Text] [Related]
50. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
Hauner H; Meier M; Wendland G; Kurscheid T; Lauterbach K; ;
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325
[TBL] [Abstract][Full Text] [Related]
51. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
Henderson DC; Copeland PM; Daley TB; Borba CP; Cather C; Nguyen DD; Louie PM; Evins AE; Freudenreich O; Hayden D; Goff DC
Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798
[TBL] [Abstract][Full Text] [Related]
52. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes.
Hung YJ; Chen YC; Pei D; Kuo SW; Hsieh CH; Wu LY; He CT; Lee CH; Fan SC; Sheu WH
Diabet Med; 2005 Aug; 22(8):1024-30. PubMed ID: 16026368
[TBL] [Abstract][Full Text] [Related]
53. [Sibutramine administration in polycystic ovary syndrome treatment].
Olszanecka-Glinianowicz M; Zahorska-Markiewicz B; Jochemczyk-Banek U; Banaś M; Zurakowski A
Ginekol Pol; 2004 Jun; 75(6):470-4. PubMed ID: 15524424
[TBL] [Abstract][Full Text] [Related]
54. Effects of sibutramine on resting metabolic rate and weight loss in overweight women.
Seagle HM; Bessesen DH; Hill JO
Obes Res; 1998 Mar; 6(2):115-21. PubMed ID: 9545017
[TBL] [Abstract][Full Text] [Related]
55. [The effect of sibutramine on weight loss in obese adolescents].
Franco RR; Cominato L; Damiani D
Arq Bras Endocrinol Metabol; 2014 Apr; 58(3):243-50. PubMed ID: 24863086
[TBL] [Abstract][Full Text] [Related]
56. Randomized trial of lifestyle modification and pharmacotherapy for obesity.
Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Phelan S; Cato RK; Hesson LA; Osei SY; Kaplan R; Stunkard AJ
N Engl J Med; 2005 Nov; 353(20):2111-20. PubMed ID: 16291981
[TBL] [Abstract][Full Text] [Related]
57. Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.
Seimon RV; Espinoza D; Ivers L; Gebski V; Finer N; Legler UF; Sharma AM; James WP; Coutinho W; Caterson ID
Int J Obes (Lond); 2014 Sep; 38(9):1165-71. PubMed ID: 24406481
[TBL] [Abstract][Full Text] [Related]
58. Sibutramine--a review of clinical efficacy.
Lean ME
Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S30-6; discussion 37-9. PubMed ID: 9130039
[TBL] [Abstract][Full Text] [Related]
59. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
Scholze J; Grimm E; Herrmann D; Unger T; Kintscher U
Circulation; 2007 Apr; 115(15):1991-8. PubMed ID: 17404163
[TBL] [Abstract][Full Text] [Related]
60. Sibutramine. A review of its contribution to the management of obesity.
McNeely W; Goa KL
Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
